Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | ABL1 | P00519 | 1/20 | 0.68 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.52 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733368 | 1.00 | POLB (0.76) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL28795634 | 1.00 | POLB (0.76) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL264066 | 1.00 | POLB (0.76) | POLBABL1RIN1P2RY6P2RY14 | |
| Phosphoric Acid SCHEMBL23748501 | 0.97 | POLB (0.72) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL6524192 | 0.95 | POLB (0.70) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL9706035 | 0.94 | POLB (0.68) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL14429249 | 0.93 | POLB (0.72) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL14568629 | 0.93 | POLB (0.72) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL14568644 | 0.93 | POLB (0.72) | POLBABL1RIN1P2RY6P2RY14 | |
| SCHEMBL14429239 | 0.93 | POLB (0.72) | POLBABL1RIN1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114652836-A | T3SS small-molecule inhibitor and screening method and application thereof | 山东大学 | 2022-06-24 | — | — | CN | claimed |
| CN-114369123-A | Efficient preparation method of 5' -aminodeoxynucleoside | 山东明化新材料有限公司 | 2022-04-19 | — | — | CN | claimed |
| EP-0548189-B1 | A METHOD OF LINKING NUCLEOSIDES WITH A SILOXANE BRIDGE | STERLING WINTHROP INC (US) | 1994-12-28 | — | — | EP | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| EP-4606903-A1 | METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEOSIDE CONTAINING PROTECTING GROUP, AND COMPOSITION | Asymchem Life Science (Tianjin) Co., Ltd (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-20250242036-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | APOSENSE LTD. (IL) | 2025-07-31 | — | — | US | disclosed |
| EP-4590338-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | Aposense Ltd. (IL) | 2025-07-30 | — | — | EP | disclosed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-3681897-B1 | N4-MODIFIED CYTIDINE NUCLEOTIDES AND THEIR USE | UNIV VILNIUS (LT) | 2025-05-14 | — | — | EP | disclosed |
| EP-4516901-A1 | A METHOD FOR SCREENING OF HYDROLYTIC ENZYMES | Vilnius University (LT) | 2025-03-05 | — | — | EP | disclosed |
| EP-0168342-A1 | Process for the preparation of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| EP-0146785-A1 | Process for the preparation of protease inhibitors | CIBA-GEIGY AG (CH) | 1985-07-03 | — | — | EP | disclosed |
| EP-0061746-B1 | PHOSPHORAMIDITE COMPOUNDS AND THEIR USE IN PRODUCING OLIGONUCLEOTIDES | UNIVERSITY PATENTS, INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| US-4500707-A | Nucleosides useful in the preparation of polynucleotides | UNIVERSITY PATENTS, INC. (US) | 1985-02-19 | — | — | US | disclosed |
| US-4457867-A | VIRICIDES, ANTITUMOR | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-07-03 | — | — | US | disclosed |
| EP-0083777-A1 | Physiologically active peptide with between 147 and 162 amino acid residues | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-07-20 | — | — | EP | disclosed |
| EP-0073826-A1 | RAPID SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES USING PHOSPHORUS OXYCHLORIDE ACTIVATION | BIORESEARCH INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| EP-0061746-A1 | Phosphoramidite compounds and their use in producing oligonucleotides | UNIVERSITY PATENTS, INC. (US) | 1982-10-06 | — | — | EP | disclosed |
| WO-1982003079-A1 | RAPID SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES USING PHOSPHORUS OXYCHLORIDE ACTIVATION | BIORESEARCH INC (US) | 1982-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242036-A1 | TRANS-MEMBRANE DELIVERY SYSTEMS AND USES THEREOF | HAVCR2, SLC47A2, SLC47A1 | POLB 1430/4885ABL1 1904/4885RIN1 1615/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | POLB 25/4885ABL1 1538/4885RIN1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.